Topics
Glioblastoma | Treatment | Targeted therapy | Relatlimab
Home > Publications > Topics > Glioblastoma > Treatment > Targeted therapy > Relatlimab
Ipilumab, Nivolumab, Relatlimab
Long GV, Shklovskaya E, Satgunaseelan L, Mao Y, da Silva IP, Perry
KA, Diefenbach RJ, Gide TN, Shivalingam B, Buckland ME, Gonzalez
M, Caixeiro N, Vergara IA, Bai X, Rawson RV, Hsiao E, Palendira U,
Phan TG, Menzies AM, Carlino MS, Quek C, Grimmond SM, Vissers JHA,
Yeo D, Rasko JEJ, Khasraw M, Neyns B, Reardon DA, Ashley DM,
Wheeler H, Back M, Scolyer RA, Drummond J, Wilmott JS, Rizos H.
Neoadjuvant triplet immune checkpoint
blockade in newly diagnosed glioblastoma.
Nat
Med. 2025 Feb 27. doi:
10.1038/s41591-025-03512-1. PMID:
40016450. Case report. ˍ